:

Qingwang Ye1, Yi Yu2, Shujie Pang3

  • 1Department of Hepatobiliary Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China.

Frontiers in immunology
|October 23, 2025
PubMed
概括

这项研究开发了一种名谱,用于预测MVI阴性肝细胞癌 (HCC) 患者的无复发生存期 (RFS). 该模型准确地识别出患有复发风险的患者,有助于为HCC提供个性化治疗策略.

相关概念视频